100 Years of the Warburg Effect and Endocrine Cancer

You are looking at 1 - 3 of 3 items for

  • Refine by access: All content x
Clear All
Francesca Ruggieri Division of Oncology, Medical University of Graz, Graz, Austria
Research Unit “Non-Coding RNAs and Genome Editing in Cancer”, Division of Oncology, Medical University of Graz, Graz, Austria

Search for other papers by Francesca Ruggieri in
Google Scholar
PubMed
Close
,
Katharina Jonas Division of Oncology, Medical University of Graz, Graz, Austria
Research Unit “Non-Coding RNAs and Genome Editing in Cancer”, Division of Oncology, Medical University of Graz, Graz, Austria

Search for other papers by Katharina Jonas in
Google Scholar
PubMed
Close
,
Manuela Ferracin Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy

Search for other papers by Manuela Ferracin in
Google Scholar
PubMed
Close
,
Michael Dengler Division of Oncology, Medical University of Graz, Graz, Austria

Search for other papers by Michael Dengler in
Google Scholar
PubMed
Close
,
Vanessa Jӓger Division of Oncology, Medical University of Graz, Graz, Austria

Search for other papers by Vanessa Jӓger in
Google Scholar
PubMed
Close
, and
Martin Pichler Division of Oncology, Medical University of Graz, Graz, Austria
Research Unit “Non-Coding RNAs and Genome Editing in Cancer”, Division of Oncology, Medical University of Graz, Graz, Austria
Department of Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany
Translational Oncology, University Hospital of Augsburg, Augsburg, Germany

Search for other papers by Martin Pichler in
Google Scholar
PubMed
Close

Cancer cells reprogram their metabolism to support their growth. Since the discovery of the Warburg effect, several other metabolic alterations and metabolites have been described in cancer cells, including lactate, glutamine, and lipid metabolism reprogramming. Together these alterations provide rapidly dividing tumor cells with metabolic intermediates needed for nucleotide, protein, and fatty acid biosynthesis. MicroRNAs are a class of small non-coding RNAs involved in the regulation of virtually all biological pathways. Altered microRNA expression patterns are associated with the onset and development of several diseases, including cancer. Tumor suppressor microRNAs targeting molecules involved in tumor metabolism are frequently downregulated in cancers. Therefore, microRNAs can serve as potential tumor biomarkers and also represent interesting therapeutic targets. This review summarizes recent findings about microRNAs involved in the regulation of tumor metabolism.

Free access
Kaylee B Punter Department of Biomedical and Medical Sciences, Queen’s University, Kingston, Canada

Search for other papers by Kaylee B Punter in
Google Scholar
PubMed
Close
,
Charles Chu Department of Biomedical and Medical Sciences, Queen’s University, Kingston, Canada

Search for other papers by Charles Chu in
Google Scholar
PubMed
Close
, and
Edmond Y W Chan Department of Biomedical and Medical Sciences, Queen’s University, Kingston, Canada

Search for other papers by Edmond Y W Chan in
Google Scholar
PubMed
Close

It has long been recognised that cancer cells critically depend on reprogrammed patterns of metabolism that can enable robust and abnormally high levels of cell proliferation. As mitochondria form hubs of cellular metabolic activity, it is reasonable to propose that pathways within these organelles can form targets that can be manipulated to compromise the ability of cancer cells to cause disease. However, mitochondria are highly multi-functional, and the full range of mechanistic inter-connections are still being unravelled to enable the full potential of targeting mitochondria in cancer therapeutics. Here, we aim to highlight the potential of modulating mitochondrial dynamics to target key metabolic or apoptotic pathways in cancer cells. Distinct roles have been demonstrated for mitochondrial fission and fusion in different cancer contexts. Targeting of factors mediating mitochondrial dynamics may be directly related to impairment of oxidative phosphorylation, which is essential to sustain cancer cell growth and can also alter sensitivity to chemotherapeutic compounds. This area is still lacking a unified model, although further investigation will more comprehensively map the underlying molecular mechanisms to enable better rational therapeutic strategies based on these pathways.

Free access
D Grahame Hardie Division of Cell Signalling & Immunology, School of Life Sciences, University of Dundee, Dundee, Scotland, UK

Search for other papers by D Grahame Hardie in
Google Scholar
PubMed
Close

Otto Warburg published the first paper describing what became known as the Warburg effect in 1923. All that was known about glucose metabolism at that time was that it occurred in two stages: (i) fermentation (glycolysis) in which glucose was converted to lactate, which did not require oxygen, and (ii) oxidative metabolism, in which the carbon atoms derived from glycolysis were fully oxidized to carbon dioxide, which did require oxygen. Warburg discovered that most tumour tissues produced a large amount of lactate that was reduced but not eliminated in the presence of oxygen, while most normal tissues produced a much smaller amount of lactate that was eliminated by the provision of oxygen. These findings were clearly well ahead of their time because it was another 80 years before they were to have any major impact, and even today the mechanisms underlying the Warburg effect are not completely understood.

Free access